 |
|
|
| |
Efficacy and Safety of Long-Acting Subcutaneous
Lenacapavir in Heavily Treatment-Experienced People
With Multi-Drug Resistant HIV:
Week 52 Results
|
| |
| |
IDWeek 2022 Oct 19-23
Onyema Ogbuagu,1 Sorana Segal-Maurer,2 Winai Ratanasuwan,3 Benoit Trottier,4
Jason Brunetta,5 Takuma Shirasaka,6 Ellen L. Koenig,7 Hui Wang,8 Nicolas Margot,8
Hadas Dvory-Sobol,8 Martin S. Rhee,8 Jared M. Baeten,8 Jean-Michel Molina9
1Yale University, New Haven, CT; 2New York Presbyterian-Queens, NY; 3Siriraj Hospital, Mahidol University, Bangkok, Thailand; 4Clinique de médecine urbaine du Quartier Latin, Montréal, Canada; 5Maple Leaf Research, Toronto, Canada; 6National Hospital Organization Osaka National Hospital, Osaka, Japan; 7Instituto Dominicano de Estudios Virologicos (IDEV), Santo Domingo, Dominican Republic; 8Gilead Sciences, Inc., Foster City, CA; 9Université Paris Cité, Paris, France
|
| |
|
|
|
|
|
